Background: The vascular endothelial growth factor (VEGF) pathway can be targeted through VEGF neutralization or VEGF receptor (VEGFR) blockade using tyrosine kinase inhibition. Because laboratory models suggest that combining these approaches might be synergistic, we sought to evaluate the feasibility and efficacy of combining sunitinib with paclitaxel + bevacizumab (PB).
introduction Vascular endothelial growth factor (VEGF)-mediated angiogenesis appears to play a pivotal role in the growth and progression of breast cancer [1, 2] . Adding the VEGFneutralizing antibody bevacizumab to chemotherapy improves response rates and time to progression in advanced breast cancer [3] [4] [5] . VEGF mediates activity through binding to the VEGF receptor (VEGFR), triggering a variety of changes in endothelial cell function and, possibly, tumor cell biology [6] . Other agents that target important mediators of angiogenesis are in development, including small molecule tyrosine kinase inhibitors that affect the function of multiple kinases thought critical to the angiogenic pathway, such as VEGFR, plateletderived growth factor receptor (PDGFR), and c-kit.
Laboratory models have suggested that simultaneous 'outside/inside' targeting of the VEGF ligand and the intracellular kinase domain of its receptor VEGFR2 can result in enhanced antitumor efficacy (G. Plowman, personal communication). A further rationale for combined outside/ inside targeting of VEGF comes from clinical studies of VEGFR inhibitor therapy with sunitinib. In both animal models of tumor growth [7] , and in breast cancer patients treated with sunitinib [8] , sunitinib treatment leads to compensatory increases in measurable levels of circulating VEGF. This observation suggests that combining anti-VEGF agents in an outside/inside approach may provide synergistic activity, and possibly overcome resistance mechanisms from single-agent anti-VEGF therapy [9, 10] .
Neither the clinical efficacy nor tolerance of pairing VEGF/ VEGFR inhibitors has been established. Each approach carries unique side-effects. Bevacizumab has been associated with hypertension, impaired wound healing, proteinuria, and concerns over bleeding and thrombosis risks. Sunitinib treatment is associated with fatigue, anorexia, taste disturbance, nausea/vomiting, and myelosuppression, and concerns over thyroid dysfunction. For this reason, a randomized phase 2 trial [Studies Assessing the Blockade of both VEGF Receptor and Ligand to enhance Efficacy in Breast (SABRE-B)] was designed to examine the feasibility of adding sunitinib to the wellstudied bevacizumab and paclitaxel combination as first-line treatment of metastatic breast cancer. methods study design and treatment plan SABRE-B was a phase II randomized open-label multicenter trial. Dosing was planned around the standard doses of paclitaxel plus bevacizumab as determined in Eastern Cooperative Oncology Group (ECOG) 2100 [4] . Sunitinib as monotherapy is typically administered at a dose of 50 mg p.o. daily for 28 days in a 6-week cycle [8] . Because data for the use of bevacizumab, paclitaxel and sunitinib in combination were not available, and based on prior reports of phase 1 safety with the drug, the starting dose of sunitinib in the study was lowered to 25 mg p.o. daily for 21 days of each 28-day cycle [11] .
Three treatment arms (one control arm and two sunitinib doseescalation arms) were planned for evaluation: bevacizumab 10 mg/kg i.v. every other week plus paclitaxel 90 mg/m 2 (PB; control arm); bevacizumab 10 mg/kg i.v. every other week plus paclitaxel 90 mg/m 2 plus 25 mg/day sunitinib (PBS; 25 mg, comparator arm); and bevacizumab 10 mg/kg i.v. every other week plus paclitaxel 90 mg/m 2 plus 37.5 mg/day sunitinib (PBS 37.5 mg, comparator arm). Paclitaxel dosing was once a week for 21 days of a 28-day cycle and sunitinib was given daily for 21 days of a 28-day cycle.
Randomization was planned in three enrollment phases, as described in Figure 1 . First, an initial two-arm phase (PB versus PBS 25 mg/day) was planned to determine the tolerability of the PBS at the 25 mg dose of sunitinib. If the PBS 25 mg arm was deemed tolerable by external safety review, a three-arm stage was planned including randomization to PB alone or PBS with sunitinib at either 25 or 37.5 mg daily depending on the tolerability of the 37.5 mg dose. In the final two-arm phase (PB and the selected PBS arm), enrollment into both treatment arms was to continue until full enrollment of the selected PBS arm. A total study size of 120-145 patients was planned, with a goal of at least 50 patients on each of the sunitinib dose arms.
patient population
Eligible patients had HER2-negative metastatic breast cancer, with either measurable (as per RECIST [12] ) or nonmeasurable disease. No prior chemotherapy for metastatic disease was allowed, and patients had to have completed any prior (neo) adjuvant chemotherapy at least 6 months before enrollment, and any prior taxane therapy at least 12 months before enrollment. Prior hormonal therapy for hormone receptor-positive disease was allowed. Prior exposure to sunitinib or bevacizumab was not permitted. Patients with brain metastases were eligible if they had received treatment of the central nervous system disease, were free of neurological symptoms, and did not require ongoing dexamethasone or full-dose anticoagulation therapy. Other eligibility criteria included ECOG performance status of 0 or 1, adequate left ventricular function at study entry, defined as an left ventricular ejection fraction >50% by either multigated acquisition scan or echocardiogram, adequate hepatic [(aspartate aminotransferase/alanine aminotransferase £2· upper limit of normal (ULN), total bilirubin £1.5 mg/dl] and renal (serum creatinine £2.0 mg/dl) function, normal coagulation parameters [partial thromboplastin time and/or either international normalized ratio (INR) or prothrombin time £1.5· ULN (except for patients receiving anticoagulation therapy)], thyroid [serum thyroid-stimulating hormone <ULN, free thyroxine >lower limit of normal (LLN), serum triiodothyronine >LLN], and bone marrow (absolute neutrophil count ‡1500/ll, platelet count ‡100 000/ll) function. Patients were excluded for inadequately controlled blood pressure, congestive heart failure, proteinuria, prior history of myocardial infarction, unstable angina, stroke, or transient ischemic attack within 12 months; history of abdominal fistula or gastrointestinal (GI) perforation within 6 months; or 
efficacy and toxicity assessments
Patients who received at least one dose of sunitinib, bevacizumab, or paclitaxel were evaluable for safety or response. Response was assessed after every third cycle (12 weeks) using RECIST criteria. Progression-free survival (PFS) during first-line therapy was defined as the time from randomization to documented disease progression or death during first-line therapy, whichever occurred first.
Adverse events (AEs) occurring on or after the first study treatment were summarized by event forms and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0. Planned dose modifications for sunitinib (25 to 12.5 mg/day) and paclitaxel (90 to 65 mg/m 2 ) were available in the setting of unacceptable toxicity including grade 2 fatigue, hand-foot syndrome, stomatitis, congestive heart failure, or recurrent grade 3 hematologic toxicity. Bevacizumab dose modification was not planned. Drug therapy would be discontinued for uncontrolled hypertension, severe or recurrent hemorrhage, arterial thrombotic event, grade 3 congestive heart failure, grade 4 proteinuria, GI perforation, wound dehiscence, or other grade 4 or nonresolving grade 3 events. Safety outcome parameters compiled included incidence of serious AEs; CTCAE grade ‡3 AEs; AEs leading to sunitinib discontinuation, dose interruption, or dose reduction; and AEs leading to bevacizumab discontinuation or dose interruption. An external safety advisory board (SAB) was created by the study sponsor for interval consultation regarding protocol continuation based on safety signals detected through periodic review. The predetermined trigger for review of the data with the safety advisory board was when at least six patients had been treated (at least three in the PBS 25 mg arm and at least three in the PB arm) with a minimum of two cycles of follow-up for each patient. The objective of this meeting was to assess whether the study could proceed to the next dose level of 37.5 mg. The SAB was also to be convened after 12 patients had been treated (at least six in the PBS 37.5 mg arm and six in the PB arm) with a minimum of two cycles of follow-up for each patient.
statistical design and methodology
The primary objective of this trial was to provide a preliminary assessment of the efficacy, determined by PFS, of combining sunitinib with bevacizumab and paclitaxel relative to bevacizumab and paclitaxel alone in patients who had not previously received chemotherapy for metastatic breast cancer. Secondary end points included response rate and a detailed toxicity description by frequency and grade of combination therapy. Sample size was estimated to be 120-145 patients to obtain at least 50 randomized patients in each of the two treatment arms, depending on the PBS arm selected for full enrollment. Since the study was terminated earlier than expected because of prohibitive toxicity in the PBS treatment arm, all efficacy analyses are exploratory. Kaplan-Meier methods were used to characterize the PFS distribution for each treatment cohort including estimation of median PFS. Responses were analyzed using a tabulation of best overall response for patients who had at least one scan at baseline and post-baseline. In the absence of progression, and death within 30 days of last study treatment, data for patients who received non-protocol-specified antitumor therapy was censored at the last tumor assessment before the receipt of the nonprotocol therapy.
results patient accrual
Between March 2007 and January 2008, a total of 46 women were randomized to receive either PB (n = 23) or PBS (25 mg p.o. qd: n = 23). All patients received at least one dose of study treatment and are part of the safety-evaluable population for analysis. As described below, due to observed unacceptable rates of toxicity in the PBS arm, accrual was stopped in the first enrollment phase in January 2008 and no patients were accrued to the higher dose cohort of sunitinib 37.5 mg/day. Table 1 lists baseline demographics and characteristics of the enrolled patients.
toxicity
The addition of sunitinib to bevacizumab and chemotherapy was associated with a clinically significant increase in toxicity (Table 2) . Hematologic toxicity was more prominent in the PBS arm, including specific increases in the rates of grade 3 or 4 leukopenia, neutropenia, and febrile neutropenia. Rates of hematopoietic original article Annals of Oncology growth factor utilization were increased in the PBS arm over the PB arm (7 versus 3 uses for erythropoiesis-stimulating agents, 15 vs. 6 uses for granulocyte-stimulating factors). GI AEs, including nausea, diarrhea, and fatigue, were the most common nonhematologic toxic effects, again occurring more frequently in the PBS arm than in PB. No deaths due to AEs or progressive disease were reported during the course of the study. There were no significant differences apparent in the rates of hypertension for the PB and PBS arms (9% versus 4% grade 3/4). However, increased use of antihypertensives in the PBS arm versus the PB arm was observed (39 uses versus 26 uses). Proteinuria of greater than grade 1 was not observed with significant frequency in either arm. A single patient on the PBS arm developed grade 4 bowel perforation secondary to sigmoid diverticulitis that was successfully treated with sigmoid resection. No AEs associated with thyroid function were observed in either arm.
During the course of the study, an alert was issued in July 2008 after the observation of microangiopathic hemolytic anemia (MAHA) in a similar study of combined bevacizumab and sunitinib in patients with renal cell carcinoma [13] . At this time, screening of patients actively receiving study therapy found no cases of MAHA; subsequent new patients enrolling on study were carefully evaluated for preexisting coagulopathy or hemolysis as well. One patient, removed from study after a hypersensitivity reaction to her first dose sunitinib, continued on paclitaxel and bevacizumab for eight additional weeks before disease progression and cessation of therapy. One month later, she was found to have evidence of hemolytic anemia, characterized by circulating schistocytes, hyperbilirubinemia, elevated lactate dehydrogenase, and low haptoglobin. Despite supportive care, she died in hospice soon after as a result of grade 5 hemolytic anemia. The anemia was clinically attributed to advanced metastatic disease; however, it is possible that the prior PBS therapy may have contributed to this toxicity. Table 3 describes dose reductions and treatment discontinuations for patients receiving PB and PBS. Substantially more protocol-defined AEs and/or toxic effects requiring dose reduction occurred with PBS than with PB. Among those receiving PBS, sunitinib dosing was interrupted for AEs in 13 (57%) patients. Ten (44%) patients required sunitinib dose reduction to 12.5 mg, and nine (39%) patients discontinued sunitinib for AEs including neutropenia (three), fatigue (three), leukopenia (two), GI perforation, diarrhea, nausea/vomiting, hyperbilirubinemia, and allergic reaction. Patients given concurrent sunitinib also were at greater risk for bevacizumab dose modification, with 61% of patients with a protocol-mandated bevacizumab hold due to toxicity issues and a greater number of patients discontinuing bevacizumab for an AE [PB arm: one patient (pulmonary embolus); PBS arm: two patients (small bowel obstruction, GI perforation, allergic reaction, neuropathy, epistaxis, and liver metastases]. A total of four patients (17%) in the PBS arm were discontinued from the study for an AE compared with none in the PB arm.
clinical observations: drug exposure and efficacy Safety data collection and review during the first enrollment phase revealed that patients in the PB arm received treatment of a longer duration (median 14.1 weeks versus 11.1 weeks), completed a greater number of bevacizumab doses (median 7.0 vs. 6.0), and had greater cumulative bevacizumab exposure compared with those in the PBS arm (median 6270 versus 3725 mg). This difference appeared to be due to a higher proportion of AEs from drug tolerability issues leading to dose reductions and treatment discontinuations in the PBS arm, as described in Table 3 .
Because of the significant toxic effects and the difficulty in delivering concurrent paclitaxel/bevacizumab/sunitinib, the planned dose escalation of sunitinib from 25 to 37.5 mg p.o. qd was not pursued. In addition, accrual to the randomization was stopped as it was not believed that the clinical experience provided adequate dosing with sunitinib/bevacizumab so as to be able to address questions of comparative efficacy between the two arms.
Given the limited number of patients enrolled and short time on treatment, a thorough investigation of prespecified efficacy 
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outcomes, including PFS and response rate, was not possible. Table 4 summarizes the best overall response for 35 assessable patients. Confirmed and unconfirmed partial response rates (61% and 71%) were comparable between the two arms; no complete responses were reported. Figure 2 shows PFS for each of the two treatment arms. Because of premature study termination and the resulting short follow-up for the PFS analysis, the median PFS was not reached.
discussion
This randomized phase II study was designed to evaluate the addition of sunitinib to paclitaxel/bevacizumab as first-line treatment of advanced breast cancer. Patients receiving the three-drug regimen exhibited an unacceptably high level of drug-related toxicity, leading to difficulty in providing ongoing therapy at the planned dosages. Major ‡grade 3 toxic effects that were observed included hematologic cytopenias, diarrhea, and fatigue. Toxic effects uniquely associated with angiogenesis inhibitors, such as hypertension, proteinuria, and MAHA, were not observed at high frequencies in either arm, though the small sample size makes exclusion of these toxic effects difficult. Total time on-study and cumulative dose received was subsequently decreased among patients receiving PBS. Due to the AE profile and high rate of dose modifications necessitated by the addition of sunitinib, the trial was stopped before completing planned dose escalation of sunitinib.
The recent proliferation of biologic agents targeting pathologic angiogenesis has led many investigators to consider combination trials that pair various antiangiogenic agents to optimize blockade of this pathway. As this study was being conducted, other investigators have reported on phase 1 experiences combining bevacizumab and sunitinib. In an advanced renal cell carcinoma population, dose escalation of sunitinib found a maximum tolerated dose (MTD) of 50 mg/day when combined with bevacizumab 10 mg/kg given every other week. However, significant class-effect hematologic and vascular toxic effects, including hypertension (83%), proteinuria (50%), thrombocytopenia (50%), and MAHA (17%), were observed at the MTD dose level. Notably, 88% of subjects in that study had undergone prior nephrectomy, possibly increasing sensitivity to certain vascular and hematologic toxic effects [13, 14] . Multiple subjects required dose reductions and almost half in the MTD cohort withdrew due to toxicity, suggesting in retrospect that the selected doses were not practical. The SABRE-B report with sunitinib 25 mg in combination with bevacizumab and paclitaxel raises similar concerns. A separate phase 1 study among patients with solid tumors escalated doses of both sunitinib and bevacizumab and achieved similar formal MTD recommendations [15] . However, significant rates of grade 3 toxic effects, including hypertension, proteinuria, and fatigue, were observed. Sorafenib, a related VEGFR-targeting agent, has been explored in combination with bevacizumab in phase 1 studies as well. In a dose escalation study in advanced solid tumors, the majority of subjects required dose reductions. Escalation to full singleagent doses was limited by toxicity, and the MTD was found to be the initial dose level [16] . A study of escalating doses of sorafenib and bevacizumab in advanced renal cell carcinoma found an MTD below typical monotherapy doses of each agent. Enhanced sorafenib-related toxicity, including rash and hypertension, was encountered in combination; however, notable activity (response rate 46%) was observed [17] .
In parallel with SABRE-B, the SABRE-L study was a randomized phase 2 study designed to explore the outcomes of adding sunitinib to a carboplatin/paclitaxel/bevacizumab backbone for first-line treatment of advanced non-small-cell original article Annals of Oncology lung cancer. The study schema mirrored SABRE-B, comprising three phases evaluating tolerability of the combination, and subsequent sunitinib dose escalation. Similar to SABRE-B, the SABRE-L trial was closed prematurely and without planned sunitinib dose escalation owing to frequent dose reductions, treatment interruptions, treatment discontinuations, and generalized increased toxicity, including hematologic toxicity and fatigue (M. Socinski, F. Scappaticci, M. Samant et al., unpublished data). Similarly, the SABRE-R study in advanced renal cell carcinoma, randomizing patients to bevacizumab with sunitinib versus placebo, was also closed prematurely for toxicity after enrolling 16 patients. MAHA was observed in SABRE-R, however not in SABRE-L or B, suggesting that toxicity may be specific to the renal cell carcinoma population [14, 18] . The above experiences, along with those presented in this manuscript, suggest that caution needs to be exercised when pairing VEGF/VEGFR-targeted drugs, either when given by themselves or in combination with chemotherapy. Determining proper doses of targeted agents in biologic combinations poses significant challenges as appropriate biologic activity may be achieved at pharmacological levels below those that lead to clinical activity [19] . Randomized trials in lung and breast cancer populations have demonstrated significant activity from reduced dose bevacizumab over placebo, suggesting optimal dosing of bevacizumab may not be conclusively defined [3, 20] . Furthermore, although anti-VEGF agents possess a specific target, either VEGF or VEGFR, methods to accurately identify tumors preferentially sensitive to these therapies are lacking. Recent studies have suggested class effect side-effects of angiogenesis inhibitors, particularly hypertension, may have a role as pharmacodynamic markers associated with better outcomes in cancer patients [21, 22] . It is possible that a different dosing strategy of bevacizumab and sunitinib may have permitted concurrent administration of these agents with or without chemotherapy; future trials will be needed to explore these possibilities. In the interim, in spite of the promising preclinical data and the commercial availability of these two medications, combination therapy using bevacizumab and sunitinib should not be attempted outside of a clinical trial.
Despite the significant additive toxicity observed in the SABRE-B trial and related studies, the question of combining outside/inside treatment approaches for inhibition of the VEGF pathway remains compelling based on preclinical data and existing clinical observations. Combination therapy using a monoclonal antibody and a tyrosine kinase inhibitor has shown promise in other pathways in breast cancer, namely HER2 [23] , and significant interest remains in pursuing biologic combination therapies in the care of patients with malignancies. Although SABRE-B attempted to develop a successful therapeutic regimen, the dosing proved, in retrospect, too ambitious. New and more feasible strategies for safely pairing anti-VEGF and anti-VEGFR-targeted treatments will be needed to effectively compare whether such an approach would be better than targeting one portion of the pathway at a time.
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